1.18% 0.0071

Handel nachbörslich: .59 -0.02 -3.28%

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten

The Potential Rise in the Price of BioXcel Therapeutics Inc (BTAI) following insiders activity - Knox Daily

BioXcel Therapeutics Inc: Weathering Stock Market Storms with 24.56M Market Cap - The InvestChronicle

Taking on analysts’ expectations and winning: BioXcel Therapeutics Inc (BTAI) - SETE News

BioXcel Therapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia

BioXcel Therapeutics stock hits 52-week low at $0.53 - Investing.com

BTAI underperforms with a -2.28 decrease in share price - US Post News

Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World

Is it a good time to sell Xcel Energy, Inc. [XEL] shares after an insider sold 2,041 shares? - Knox Daily

Blair William & Co. IL Has $2.01 Million Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World

New Haven-based BioXcel faces delisting from Nasdaq stock exchange - Hartford Business Journal

Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex

Charting the Course: BioXcel Therapeutics Inc’s BTAI Stock Prospects - The InvestChronicle

Xcel Energy Inc. (NASDAQ:XEL) Shares Acquired by Sei Investments Co. - Defense World

Gabelli Funds LLC Sells 12,283 Shares of Xcel Energy Inc. (NASDAQ:XEL) - Defense World

BlackSky target adjusted to $15 from $2.50 at H.C. Wainwright - TipRanks

Summit Trail Advisors LLC Boosts Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World

BlueLinx Holdings Inc. (NYSE:BXC) Shares Purchased by Massachusetts Financial Services Co. MA - Defense World

BioXcel Therapeutics faces Nasdaq delisting risk over share price - Investing.com

BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Canada

BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Australia

Meiji Yasuda Asset Management Co Ltd. Has $1.13 Million Holdings in Xcel Energy Inc. (NASDAQ:XEL) - Defense World

BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com UK

New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - CT Insider

New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - Greenwich Time

New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - Torrington Register Citizen

New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - The Advocate

BioXcel announces new priorities - The Pharma Letter

HC Wainwright Weighs in on BriaCell Therapeutics Corp.’s FY2029 Earnings (TSE:BCT) - Defense World

BioXcel Therapeutics (NASDAQ:BTAI) & Xenon Pharmaceuticals (NASDAQ:XENE) Head to Head Review - Defense World

Xcel Energy receives hold rating with $70 price target from Jefferies - Investing.com

BioXcel stock gains after new strategic focus (NASDAQ:BTAI) - Seeking Alpha

BioXcel Therapeutics refocuses on BXCL501 clinical trials - Investing.com

BioXcel Therapeutics announces workforce reduction to prioritize lead asset - Investing.com

New Haven-based BioXcel lays off 28% of workforce, including chief commercial officer - Hartford Business Journal

BioXcel Therapeutics refocuses on BXCL501 clinical trials By Investing.com - Investing.com Australia

BioXcel Therapeutics refocuses on BXCL501 clinical trials By Investing.com - Investing.com Canada

BioXcel announces clinical prioritization of late-stage BXCL501 programs - TipRanks

Bioxcel Therapeutics Announces Restructuring and Leadership Changes - TipRanks

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - GlobeNewswire

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - StockTitan

BioXcel Therapeutics CSO sells $244 in stock - Investing.com India

Bioxcel therapeutics executive sells over $148 in stock By Investing.com - Investing.com Australia

Bioxcel therapeutics executive sells over $148 in stock By Investing.com - Investing.com Canada

Bioxcel therapeutics executive sells over $148 in stock By Investing.com - Investing.com South Africa

BioXcel Therapeutics CEO sells over $1,300 in stock - Investing.com India

BioXcel Therapeutics CSO sells $244 in stock By Investing.com - Investing.com Australia

BioXcel Therapeutics executive sells shares worth $238 - Investing.com

BioXcel Therapeutics CEO sells over $1,300 in stock - Investing.com

Bioxcel therapeutics executive sells over $148 in stock - Investing.com

BioXcel Therapeutics CEO sells over $1,300 in stock By Investing.com - Investing.com UK

What is BioXcel Therapeutics Inc (BTAI) Stock Return on Shareholders’ Capital? - SETE News

why BioXcel Therapeutics Inc [BTAI] is a Good Choice for Investors After New Price Target of $4.60 - The DBT News

BioXcel Therapeutics CSO sells $244 in stock By Investing.com - Investing.com Canada

BTAI’s price-to-book ratio: An indicator of the company’s performance - US Post News

BioXcel Therapeutics Inc (BTAI) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares - Yahoo Finance

BioXcel advances Alzheimer's agitation treatment - Investing.com

BioXcel Therapeutics Inc [BTAI] Insider Activity: An Update for Investors - Knox Daily

Mizuho maintains Neutral rating on BioXcel shares By Investing.com - Investing.com Canada

BioXcel Therapeutics (NASDAQ:BTAI) Stock Rating Reaffirmed by HC Wainwright - Defense World

BioXcel Therapeutics Q1 2024 Earnings Preview - MSN

BioXcel Therapeutics stock hits 52-week low at $0.58 - Investing.com

BioXcel Therapeutics keeps stock target, buy rating on trial update By Investing.com - Investing.com Canada

BioXcel Therapeutics stock hits 52-week low at $0.58 By Investing.com - Investing.com UK

BioXcel Therapeutics begins Phase 3 trial for agitation treatment - Investing.com

BioXcel Therapeutics begins Phase 3 trial for agitation treatment By Investing.com - Investing.com UK

BioXcel Therapeutics Announces Initiation of SERENITY - GlobeNewswire

Ähnlich wie BTAI